Compare Asana Inc. (ASAN) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs BridgeBio Pharma Inc — how do they compare? Asana Inc. trades at $9.25 (market cap $2.13B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 7.8× Asana Inc.'s market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | BBIO | |
|---|---|---|
Market Cap | $2.13B | $16.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $90.17 |
52-Week Low | $5.46 | $47.29 |
Enterprise Value | $1.95B | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.26, up 6.68% today, with a bullish technical signal from moving averages and a consensus price target of $10.33. Recent quarterly earnings have consistently beaten expectations, including Q1 2027 EPS of $0.10 versus $0.08 expected. Revenue growth is steady, reaching $724 million in 2025, but profitability remains negative with a net margin of -20.21%. The company is advancing its AI capabilities, highlighted by the StackAI acquisition announced on May 28, 2026.
The outlook is mixed: strong revenue growth and AI innovation support upside potential, but persistent losses and intense competition from Microsoft and Alphabet pose significant risks. Analyst sentiment is divided, with 42% buy ratings. Earnings momentum is key for sustained gains.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
